Nkarta (NKTX) Common Equity (2019 - 2026)
Nkarta's quarterly Common Equity came in at $285.9 million in Q1 2026, down 24.54% year-on-year from $378.8 million in Q1 2025, and down 8.47% quarter-over-quarter from $312.3 million in Q4 2025.
Nkarta has reported Common Equity for 8 years, with the latest figure at $285.9 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 24.54% year-over-year to $285.9 million; the trailing twelve-month figure through Mar 2026 stood at $285.9 million (down 24.54% YoY), and the FY2025 full-year result was $312.3 million, down 23.45% from the prior year.
- Common Equity for Q1 2026 stood at $285.9 million, down from $312.3 million in the prior quarter.
- The five-year high for Common Equity was $473.7 million in Q1 2024, with the low at $228.7 million in Q1 2022.
- Average Common Equity over 5 years is $358.5 million, with a median of $357.7 million recorded in 2025.
- Peak annual rise in Common Equity reached 51.57% in 2023, while the deepest fall reached 26.58% in 2023.
- Tracing NKTX's Common Equity over 5 years: stood at $372.2 million in 2022, then fell by 26.58% to $273.3 million in 2023, then soared by 49.29% to $408.0 million in 2024, then fell by 23.45% to $312.3 million in 2025, then declined by 8.47% to $285.9 million in 2026.
- The last three Common Equity figures came in at $285.9 million (Q1 2026), $312.3 million (Q4 2025), and $337.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 285.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285.86 Mn |
| Dec 31, 2025 | 312.33 Mn |
| Sep 30, 2025 | 337.90 Mn |
| Jun 30, 2025 | 357.67 Mn |
| Mar 31, 2025 | 378.81 Mn |
| Dec 31, 2024 | 407.98 Mn |
| Sep 30, 2024 | 430.87 Mn |
| Jun 30, 2024 | 453.18 Mn |
| Mar 31, 2024 | 473.65 Mn |
| Dec 31, 2023 | 273.29 Mn |
| Sep 30, 2023 | 296.82 Mn |
| Jun 30, 2023 | 317.98 Mn |
| Mar 31, 2023 | 346.65 Mn |
| Dec 31, 2022 | 372.21 Mn |
| Sep 30, 2022 | 399.26 Mn |
| Jun 30, 2022 | 421.04 Mn |
| Mar 31, 2022 | 228.71 Mn |
| Dec 31, 2021 | 250.97 Mn |
| Sep 30, 2021 | 270.01 Mn |
| Jun 30, 2021 | 288.38 Mn |
| Mar 31, 2021 | 305.99 Mn |
| Dec 31, 2020 | 321.22 Mn |
| Sep 30, 2020 | 334.98 Mn |
| Jun 30, 2020 | -83.89 Mn |
| Mar 31, 2020 | -33.69 Mn |
| Dec 31, 2019 | -25.48 Mn |
| Sep 30, 2019 | -15.57 Mn |
| Jun 30, 2019 | -13.14 Mn |